Bayer is set to significantly expand its footprint in the U.S. pharmaceutical sector, designating drug development in the country as a “cornerstone” of its global strategy. The announcement, highlighted in the San Diego Business Journal, underscores the company’s commitment to leveraging the region’s robust biotech ecosystem to accelerate innovation and bring new therapies to market. This move signals a strategic pivot aimed at enhancing Bayer’s competitiveness and addressing critical healthcare needs through advanced research and development efforts centered in the United States.
Bayer Commits Major Investment to U.S. Drug Innovation
Bayer has announced a significant capital infusion aimed at bolstering its pharmaceutical research capabilities across key U.S. hubs,…
—-
Author : Miles Cooper
Publish date : 2025-12-30 18:56:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
